Centivax Initiates Phase 1 First-In-Human Clinical Trial Of Universal Flu Vaccine
ReutersFeb 12, 2026 4:34 PM
Feb 12 (Reuters) - CENTIVAX:
CENTIVAX INITIATES PHASE 1 FIRST-IN-HUMAN CLINICAL TRIAL OF UNIVERSAL FLU VACCINE
CENTIVAX: FIRST DATA, IN 180 SUBJECTS, IS EXPECTED WITHIN YEAR
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
8 hours ago
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
11 hours ago
Best AI Tools for Stock Analysis in 2026 to Boost Your Investment Portfolio
As Artificial Intelligence (AI) continues to enhance everyday decision-making, these tools will allow us to leverage artificial intelligence to analyse stocks and optimise our investment portfolio.TradingKey
Wed, Feb 11
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
Wed, Feb 11
